聚氨基酸基传递体系用于循环恶性细胞的基因编辑及疗效评估

漆李矜; 韩笛; 任肖荷; 何晓燕; 郭涛; 张先正; 程巳雪

doi:10.11777/j.issn1000-3304.2024.24196

您当前的位置：

首页 >

文章列表页 >

聚氨基酸基传递体系用于循环恶性细胞的基因编辑及疗效评估

研究论文 | 更新时间：2025-01-24

- 聚氨基酸基传递体系用于循环恶性细胞的基因编辑及疗效评估
- Poly(amino acid)-based Delivery Systems for Genome Editing and Therapeutic Efficacy Evaluation in Circulating Malignant Cells
- 高分子学报 2025年56卷第2期页码：253-265
- 作者机构：
  
  1.生物医用高分子材料教育部重点实验室武汉大学化学与分子科学学院武汉 430072
  2.安徽医科大学生命科学学院合肥 230011
  3.安徽医科大学第一附属医院合肥 230011
- 作者简介：
  
  E-mail: chengsixue@whu.edu.cn
- 基金信息：
  
  国家自然科学基金基础科学中心项目(基金号 51988102)
- DOI：10.11777/j.issn1000-3304.2024.24196
  中图分类号：
- CSTR：32057.14.GFZXB.2024.7292
- 纸质出版日期：2025-02-20，
  
  网络出版日期：2024-11-22，
  
  收稿日期：2024-07-14，
  
  录用日期：2024-09-06
- 稿件说明：
移动端阅览
漆李矜, 韩笛, 任肖荷, 何晓燕, 郭涛, 张先正, 程巳雪. 聚氨基酸基传递体系用于循环恶性细胞的基因编辑及疗效评估[J]. 高分子学报, 2025,56(2):253-265.

LI-JIN QI, DI HAN, XIAO-HE REN, XIAO-YAN HE, TAO GUO, XIAN-ZHENG ZHANG, SI-XUE CHENG. Poly(amino acid)-based Delivery Systems for Genome Editing and Therapeutic Efficacy Evaluation in Circulating Malignant Cells. [J]. Acta polymerica sinica, 2025, 56(2): 253-265.
漆李矜, 韩笛, 任肖荷, 何晓燕, 郭涛, 张先正, 程巳雪. 聚氨基酸基传递体系用于循环恶性细胞的基因编辑及疗效评估[J]. 高分子学报, 2025,56(2):253-265. DOI： 10.11777/j.issn1000-3304.2024.24196. CSTR： 32057.14.GFZXB.2024.7292.

LI-JIN QI, DI HAN, XIAO-HE REN, XIAO-YAN HE, TAO GUO, XIAN-ZHENG ZHANG, SI-XUE CHENG. Poly(amino acid)-based Delivery Systems for Genome Editing and Therapeutic Efficacy Evaluation in Circulating Malignant Cells. [J]. Acta polymerica sinica, 2025, 56(2): 253-265. DOI： 10.11777/j.issn1000-3304.2024.24196. CSTR： 32057.14.GFZXB.2024.7292.

摘要

肿瘤异质化和每位患者的特异性是肿瘤研究和治疗中的重要挑战，而个性化精准诊疗是解决这一挑战的关键途径之一. 本研究中，设计制备了基于聚氨基酸的肿瘤靶向传递体系，利用

-聚-

-赖氨酸负载敲除促进肿瘤发展的黏蛋白1 (MUC1)的CRISPR-Cas9质粒，外层修

饰键接了AS1411适配子的透明质酸，通过靶向肿瘤细胞表面过表达的核仁素(nucleolin)和CD44实现对肿瘤细胞的特异性高效传递和基因编辑. 进一步，利用这一靶向传递载体负载检测MUC1、肺转移标志物组织蛋白酶C (CTSC)、骨转移标志物锯齿状典型Notch配体1 (JAG1)的mRNA的3种分子信标，对基因编辑效果进行检测. 针对肿瘤细胞系BT549及乳腺癌患者外周血中的循环恶性细胞开展了基因编辑及疗效评估研究，结果表明，基因编辑传递体系可以有效靶向恶性细胞，敲除MUC1基因，抑制MUC1的表达、显著下调肺转移和骨转移标志物. 本研究利用少量全血进行个性化体外研究，可便捷高效地评估特定治疗措施的疗效，为肿瘤个性化精准治疗提供依据和参考.

Abstract

Tumor heterogeneity and the individual specificity of each patient pose a significant challenge in tumor research and treatment. Personalized precision therapy is one of the key approaches to address this challenge. In this study

tumor targeting delivery systems based on

-poly-L-lysine (

-PL) for tumor therapy and diagnosis were designed and prepared. In the therapeutic system

-PL was used to complex with the CRISPR-Cas9 plasmid for knocking out mucin 1 (MUC1)

a protein promotes tumor development

and then the complexes were decorated with AS1411 conjugated hyaluronic acid. The presence of AS1411 and hyaluronic acid chain facilitated the tumor targeting delivery of the genome editing plasmid into nucleolin and/or CD44 overexpressed tumor cells. Moreover

this target

ed delivery vector was loaded with three types of molecular beacons to detect mRNAs of MUC1

cathepsin C (CTSC

a lung metastasis biomarker)

and Notch ligand Jagged1 (JAG1

a bone metastasis biomarker)

thereby evaluating the therapeutic effects of gene editing.

In vitro

and

ex vivo

studies were conducted in the BT549 tumor cell line and circulating malignant cells from breast cancer patients. The results demonstrate that the gene editing delivery system effectively targets malignant cells

leading to knockout of MUC1 gene and downregulation of MUC1 expression. Furthermore

the genome edited malignant cells show markedly reduced mRNA biomarkers associated with lung and bone metastasis

suggesting MUC1 knockout is a promising strategy for inhibiting tumor progression and metastasis. By employing a small volume of whole blood for personalized

ex vivo

studies

this research offers a safe and convenient method for effectively evaluating the therapeutic efficacy of a specific intervention. This approach is also applicable for evaluating other treatment modalities as well as detecting various nucleic acid biomarkers

thereby offering precise information for personalized therapy.

关键词

聚氨基酸肿瘤靶向传递载体基因治疗mRNA检测

Keywords

Poly(amino acid)Tumor targetingDelivery vectorGene therapymRNA detection

references

Martínez-Jiménez F.; Muiños F.; Sentís I.; Deu-Pons J.; Reyes-Salazar I.; Arnedo-Pac C.; Mularoni L.; Pich O.; Bonet J.; Kranas H.; Gonzalez-Perez A.; Lopez-Bigas N.A compendium of mutational cancer driver genes. Nat. Rev. Cancer, 2020, 20(10), 555-572. doi:10.1038/s41568-020-0290-xhttp://dx.doi.org/10.1038/s41568-020-0290-x

Hausser J.; Alon U.Tumour heterogeneity and the evolutionary trade-offs of cancer. Nat. Rev. Cancer, 2020, 20(4), 247-257. doi:10.1038/s41568-020-0241-6http://dx.doi.org/10.1038/s41568-020-0241-6

Dagogo-Jack I.; Shaw A. T.Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol., 2018, 15(2), 81-94. doi:10.1038/nrclinonc.2017.166http://dx.doi.org/10.1038/nrclinonc.2017.166

Abdolahi S.; Ghazvinian Z.; Muhammadnejad S.; Saleh M.; Asadzadeh Aghdaei H.; Baghaei K.Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J. Transl. Med., 2022, 20(1), 206. doi:10.1186/s12967-022-03405-8http://dx.doi.org/10.1186/s12967-022-03405-8

Schambach A.; Buchholz C. J.; Torres-Ruiz R.; Cichutek K.; Morgan M.; Trapani I.; Büning H.A new age of precision gene therapy. Lancet, 2024, 403(10426), 568-582. doi:10.1016/s0140-6736(23)01952-9http://dx.doi.org/10.1016/s0140-6736(23)01952-9

Mohammadinejad R.; Dehshahri A.; Sagar Madamsetty V.; Zahmatkeshan M.; Tavakol S.; Makvandi P.; Khorsandi D.; Pardakhty A.; Ashrafizadeh M.; Ghasemipour Afshar E.; Zarrabi A.In vivo gene delivery mediated by non-viral vectors for cancer therapy. J. Control. Release, 2020, 325, 249-275. doi:10.1016/j.jconrel.2020.06.038http://dx.doi.org/10.1016/j.jconrel.2020.06.038

Wang J. H.; Gessler D. J.; Zhan W.; Gallagher T. L.; Gao G. P.Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct. Target. Ther., 2024, 9(1), 78. doi:10.1038/s41392-024-01780-whttp://dx.doi.org/10.1038/s41392-024-01780-w

Shirley J. L.; de Jong Y. P.; Terhorst C.; Herzog R. W.Immune responses to viral gene therapy vectors. Mol. Ther., 2020, 28(3), 709-722. doi:10.1016/j.ymthe.2020.01.001http://dx.doi.org/10.1016/j.ymthe.2020.01.001

Thomas C. E.; Ehrhardt A.; Kay M. A.Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet., 2003, 4(5), 346-358. doi:10.1038/nrg1066http://dx.doi.org/10.1038/nrg1066

Elzoghby A. O.; Samy W. M.; Elgindy N. A.Protein-based nanocarriers as promising drug and gene delivery systems. J. Control. Release, 2012, 161(1), 38-49. doi:10.1016/j.jconrel.2012.04.036http://dx.doi.org/10.1016/j.jconrel.2012.04.036

Hu W. K.; Ying M.; Zhang S. M.; Wang J. L.Poly(amino acid)-based carrier for drug delivery systems. J. Biomed. Nanotechnol., 2018, 14(8), 1359-1374. doi:10.1166/jbn.2018.2590http://dx.doi.org/10.1166/jbn.2018.2590

Wang L.; Zhang C. Y.; Zhang J. H.; Rao Z. M.; Xu X. M.; Mao Z. G.; Chen X. S.Epsilon-poly-L-lysine: recent advances in biomanufacturing and applications. Front. Bioeng. Biotechnol., 2021, 9, 748976. doi:10.3389/fbioe.2021.748976http://dx.doi.org/10.3389/fbioe.2021.748976

Zhu H. F.; Liu R.; Shang Y. X.; Sun L. Y.Polylysine complexes and their biomedical applications. Eng. Regen., 2023, 4(1), 20-27. doi:10.1016/j.engreg.2022.11.001http://dx.doi.org/10.1016/j.engreg.2022.11.001

Patil N. A.; Kandasubramanian B.Functionalized polylysine biomaterials for advanced medical applications: a review. Eur. Polym. J., 2021, 146, 110248. doi:10.1016/j.eurpolymj.2020.110248http://dx.doi.org/10.1016/j.eurpolymj.2020.110248

Lv P.; Zhou C.; Zhao Y. L.; Liao X. L.; Yang B.Modified-epsilon-polylysine-grafted-PEI-‍β‍-cyclodextrin supramolecular carrier for gene delivery. Carbohydr. Polym., 2017, 168, 103-111. doi:10.1016/j.carbpol.2017.02.036http://dx.doi.org/10.1016/j.carbpol.2017.02.036

Urello M. A.; Xiang L.; Colombo R.; Ma A.; Joseph A.; Boyd J.; Peterson N.; Gao C. S.; Wu H.; Christie R. J.Metabolite-based modification of poly(L-lysine) for improved gene delivery. Biomacromolecules, 2020, 21(9), 3596-3607. doi:10.1021/acs.biomac.0c00614http://dx.doi.org/10.1021/acs.biomac.0c00614

Hong C. A.; Son H. Y.; Nam Y. S.Layer-by-layer siRNA/poly(L-lysine) multilayers on polydopamine-coated surface for efficient cell adhesion and gene silencing. Sci. Rep., 2018, 8(1), 7738. doi:10.1038/s41598-018-25655-7http://dx.doi.org/10.1038/s41598-018-25655-7

Qiu L. P.; Wu C. C.; You M. X.; Han D.; Chen T.; Zhu G. Z.; Jiang J. H.; Yu R. Q.; Tan W. H.A targeted, self-delivered, and photocontrolled molecular beacon for mRNA detection in living cells. J. Am. Chem. Soc., 2013, 135(35), 12952-12955. doi:10.1021/ja406252whttp://dx.doi.org/10.1021/ja406252w

Mattheolabakis G.; Milane L.; Singh A.; Amiji M. M.Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J. Drug Target., 2015, 23(7-8), 605-618. doi:10.3109/1061186x.2015.1052072http://dx.doi.org/10.3109/1061186x.2015.1052072

Hu H. H.; Zhang Z.; Fang Y. F.; Chen L.; Wu J.Therapeutic poly(amino acid)s as drug carriers for cancer therapy. Chin. Chem. Lett., 2023, 34(6), 107953. doi:10.1016/j.cclet.2022.107953http://dx.doi.org/10.1016/j.cclet.2022.107953

Ring A.; Nguyen-Sträuli B. D.; Wicki A.; Aceto N.Biology, vulnerabilities and clinical applications of circulating tumour cells. Nat. Rev. Cancer, 2023, 23(2), 95-111. doi:10.1038/s41568-022-00536-4http://dx.doi.org/10.1038/s41568-022-00536-4

Tretyakova M. S.; Subbalakshmi A. R.; Menyailo M. E.; Jolly M. K.; Denisov E. V.Tumor hybrid cells: nature and biological significance. Front. Cell Dev. Biol., 2022, 10, 814714. doi:10.3389/fcell.2022.814714http://dx.doi.org/10.3389/fcell.2022.814714

Lin A. Y.; Wang D. D.; Li L. D.; Lin P. P.Identification and comprehensive co-detection of necrotic and viable aneuploid cancer cells in peripheral blood. Cancers, 2021, 13(20), 5108. doi:10.3390/cancers13205108http://dx.doi.org/10.3390/cancers13205108

Han D.; Ren X. H.; He X. Y.; Chen X. S.; Pang X.; Cheng S. X.Aptamer/peptide-functionalized nanoprobe for detecting multiple miRNAs in circulating malignant cells to study tumor heterogeneity. ACS Biomater. Sci. Eng., 2023, 9(10), 5832-5842. doi:10.1021/acsbiomaterials.3c01055http://dx.doi.org/10.1021/acsbiomaterials.3c01055

Han D.; He X. Y.; Huang Y.; Gao M.; Guo T.; Ren X. H.; Liao X. R.; Chen X. S.; Pang X.; Cheng S. X.A multifunctional delivery system for remodulating cell behaviors of circulating malignant cells to prevent cell fusion. Adv. Sci., 2023, 10(29), e2303309. doi:10.1002/advs.202303309http://dx.doi.org/10.1002/advs.202303309

Han D.; Ren X. H.; Liao X. R.; He X. Y.; Guo T.; Chen X. S.; Pang X.; Cheng S. X.A multiple targeting nanoprobe for identifying cancer metastatic sites based on detection of various mRNAs in circulating tumor cells. Nano Lett., 2023, 23(9), 3678-3686. doi:10.1021/acs.nanolett.2c04643http://dx.doi.org/10.1021/acs.nanolett.2c04643

Krebs M. G.; Metcalf R. L.; Carter L.; Brady G.; Blackhall F. H.; Dive C.Molecular analysis of circulating tumour cells-biology and biomarkers. Nat. Rev. Clin. Oncol., 2014, 11(3), 129-144. doi:10.1038/nrclinonc.2013.253http://dx.doi.org/10.1038/nrclinonc.2013.253

Yang G.; Song T.; Wang M.; Li M. Y.; Su Q. Q.; Xie Z. X.; Xie X. X.; Zhang H. X.; Feng Y.; Wu C. H.; Liu Y. Y.; Yang H.Recent advancements in nanosystem-based molecular beacons for RNA detection and imaging. ACS Appl. Nano Mater., 2022, 5(3), 3065-3086. doi:10.1021/acsanm.1c03966http://dx.doi.org/10.1021/acsanm.1c03966

Jin C.; Rajabi H.; Rodrigo C. M.; Porco J. A.Jr, Kufe, D. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene, 2013, 32(17), 2179-2188. doi:10.1038/onc.2012.236http://dx.doi.org/10.1038/onc.2012.236

Kufe D. W.MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene, 2013, 32(9), 1073-1081. doi:10.1038/onc.2012.158http://dx.doi.org/10.1038/onc.2012.158

Chen X. Y.; Sandrine I. K.; Yang M.; Tu J. Y.; Yuan X. L.MUC1 and MUC16: critical for immune modulation in cancer therapeutics. Front. Immunol., 2024, 15, 1356913. doi:10.3389/fimmu.2024.1356913http://dx.doi.org/10.3389/fimmu.2024.1356913

Mori Y.; Akita K.; Tanida S.; Ishida A.; Toda M.; Inoue M.; Yashiro M.; Sawada T.; Hirakawa K.; Nakada H.MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells. J. Biol. Chem., 2014, 289(51), 35193-35204. doi:10.1074/jbc.m114.586461http://dx.doi.org/10.1074/jbc.m114.586461

Khodabakhsh F.; Merikhian P.; Eisavand M. R.; Farahmand L.Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling. Cancer Cell Int., 2021, 21(1), 200. doi:10.1186/s12935-021-01899-8http://dx.doi.org/10.1186/s12935-021-01899-8

Rajabi H.; Kufe D.MUC1-C oncoprotein integrates a program of EMT, epigenetic reprogramming and immune evasion in human carcinomas. Biochim. Biophys. Acta Rev. Cancer, 2017, 1868(1), 117-122. doi:10.1016/j.bbcan.2017.03.003http://dx.doi.org/10.1016/j.bbcan.2017.03.003

Ren X. H.; Han D.; He X. Y.; Guo T.; Chen X. S.; Pang X.; Cheng S. X.Multi-targeting nano-systems targeting heterogeneous cancer cells for therapeutics and biomarker detection. Adv. Healthcare Mater., 2023, 12(4), 2202155. doi:10.1002/adhm.202202155http://dx.doi.org/10.1002/adhm.202202155

Xiao Y. S.; Cong M.; Li J. T.; He D. S.; Wu Q. Y.; Tian P.; Wang Y.; Yang S. X.; Liang C. X.; Liang Y. J.; Wen J. L.; Liu Y. J.; Luo W. Q.; Lv X. Z.; He Y. F.; Cheng D. D.; Zhou T. H.; Zhao W. J.; Zhang P. Y.; Zhang X.; Xiao Y. C.; Qian Y. C.; Wang H. X.; Gao Q.; Yang Q. C.; Yang Q. F.; Hu G. H.Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. Cancer Cell, 2021, 39(3), 423-437. doi:10.1016/j.ccell.2020.12.012http://dx.doi.org/10.1016/j.ccell.2020.12.012

Sethi N.; Dai X. D.; Winter C. G.; Kang Y. B.Tumor-derived jagged1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell, 2011, 19(2), 192-205. doi:10.1016/j.ccr.2010.12.022http://dx.doi.org/10.1016/j.ccr.2010.12.022

Tao J.; Erez A.; Lee B.One notch further: jagged 1 in bone metastasis. Cancer Cell, 2011, 19(2), 159-161. doi:10.1016/j.ccr.2011.01.043http://dx.doi.org/10.1016/j.ccr.2011.01.043

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

氨基酸基材料在基因与药物传递领域的应用

肿瘤诊疗多肽/聚氨基酸自组装纳米材料